Dhanya Dharman | Pharmacology | Best Research Article Award

Published on by Best Paper Awards

Best Research Article Award

Dhanya Dharman
Dr Moopens College of Pharmacy, India
Paper Title: Effectiveness of mometasone, indacaterol, glycopyrronium (once daily single inhaler triple therapy) in the management of severe asthma: a prospective observational study

Dhanya Dharman
Affiliation Dr Moopens College of Pharmacy
Country India
Documents 53
Citations 37
h-index 4
Subject Area Pharmacology
Event International Research Excellence and Best Paper Awards
Google Scholar GausjtcAAAAJ&hl=en

Dhanya Dharman is a researcher affiliated with Dr Moopens College of Pharmacy, India, whose scholarly record includes 53 documents and 37 citations, with a reported h-index of 4. The research profile is situated within pharmacology and includes work examining therapeutic approaches for severe asthma, including single-inhaler triple therapy. [1]

Abstract

Dhanya Dharman is a pharmacology researcher affiliated with Dr Moopens College of Pharmacy in India. Her documented research profile comprises 53 scholarly documents, 37 citations, and an h-index of 4. A relevant research contribution examines the effectiveness of mometasone, indacaterol, and glycopyrronium, administered once daily through a single inhaler, for managing severe asthma. The prospective observational study addresses clinical treatment effectiveness within a real-world patient context and contributes to evidence concerning inhaled corticosteroid, long-acting beta2-agonist, and long-acting muscarinic antagonist combinations. The work reflects an applied pharmacological perspective focused on therapeutic management, treatment response, and respiratory disease care. [1]

Keywords

Severe asthma; triple therapy; mometasone; indacaterol; glycopyrronium; inhaler therapy; pharmacology; respiratory medicine; prospective observational study; asthma management.

Introduction

Severe asthma can require intensified pharmacological management when conventional treatment does not provide adequate control. Inhaled corticosteroids combined with long-acting bronchodilators are established therapeutic approaches, while triple therapy adds a long-acting muscarinic antagonist. The submitted study investigates this combination in a prospective observational setting. [1]

Research Profile

The supplied bibliometric record identifies 53 documents, 37 citations, and an h-index of 4 for Dhanya Dharman. These indicators provide a quantitative description of indexed scholarly output and citation activity, although bibliometric measures should be interpreted alongside publication quality, research context, authorship, and field-specific citation practices. [1]

Research Contributions

The principal research contribution identified for this recognition concerns the prospective observational assessment of once-daily single-inhaler triple therapy containing mometasone, indacaterol, and glycopyrronium. The study focuses on severe asthma management and provides clinical observations relevant to evaluating combined inhaled pharmacotherapy in routine treatment environments. [2]

Publications

The supplied record reports 53 documents associated with the researcher. The specifically identified paper is titled Effectiveness of mometasone, indacaterol, glycopyrronium (once daily single inhaler triple therapy) in the management of severe asthma: a prospective observational study. Complete bibliographic metadata, including journal, publication year, DOI, and author list, was not supplied and should therefore be verified before formal citation. [1]

Research Impact

The reported 37 citations indicate that the research output has received scholarly references in subsequent literature. Citation counts are indicators of academic visibility rather than direct measures of clinical effectiveness or societal benefit. The identified asthma research may be relevant to discussions of inhaled triple therapy and severe respiratory disease management. [1]

Award Suitability

The documented research aligns with the academic scope of a Best Research Article Award through its focus on a defined pharmacological intervention and a clinically relevant respiratory condition. Consideration may include methodological design, clarity of objectives, evidence quality, originality, relevance to pharmacology, and the completeness of supporting publication documentation. [2]

Conclusion

Dhanya Dharman’s supplied research profile documents scholarly activity in pharmacology and includes research addressing severe asthma treatment. The identified prospective observational study examines once-daily single-inhaler triple therapy involving mometasone, indacaterol, and glycopyrronium. Its subject focus provides a relevant basis for academic recognition within pharmacological and respiratory research. [1]

References

    1. Ramesan, R. (n.d.). Google Scholar profile. Google Scholar.
      Google Scholar Profile

    2. The era of pharmacovigilance and the need of pharmacovigilance in psychiatry: A review.
      https://www.researchgate.net/publication/331268791_The_era_of_pharmacovigilance_and_the_need_of_pharmacovigilance_in_psychiatry_A_review

    3. A cross sectional study of polycystic ovarian syndrome among pharmacy students.
      https://www.researchgate.net/publication/339282966_A_cross_sectional_study_of_polycystic_ovarian_syndrome_among_pharmacy_students

Krishnaveni Manubolu | Pharmaceutical Sciences | Research Excellence Award

Published on by Best Paper Awards

Research Excellence Award

KRISHNAVENI MANUBOLU
Narayana Pharmacy College

KRISHNAVENI MANUBOLU
Affiliation Narayana Pharmacy College
Country India
Scopus ID 57222627724
Documents 29
Citations 112
h-index 7
Subject Area Pharmaceutical Sciences
Event Best Paper Awards
ORCID 0000-0002-9401-1768

KRISHNAVENI MANUBOLU is a researcher affiliated with Narayana Pharmacy College, India, whose work in pharmaceutical sciences has contributed to advancing knowledge in drug development, formulation science, and therapeutic evaluation. Her academic contributions are reflected through peer-reviewed publications indexed in international databases, demonstrating consistent scholarly engagement and research productivity [1].

Abstract

This article presents an academic overview of KRISHNAVENI MANUBOLU, highlighting her research achievements, publication record, and contributions to pharmaceutical sciences. The evaluation emphasizes her scholarly productivity, citation metrics, and alignment with criteria for research excellence recognition [1].

Keywords

  • Pharmaceutical Sciences
  • Drug Development
  • Research Impact
  • Academic Publications
  • Scopus Metrics

Introduction

Research excellence awards recognize scholars who demonstrate consistent contributions to scientific advancement. KRISHNAVENI MANUBOLU’s academic profile reflects a commitment to pharmaceutical research, supported by peer-reviewed outputs and citation-based impact indicators [1].

Research Profile

Her research profile includes 29 indexed documents with 112 citations and an h-index of 7, indicating moderate but steady scholarly influence within pharmaceutical sciences. These metrics are commonly used to assess research productivity and citation impact in academic evaluations [1].

Research Contributions

KRISHNAVENI MANUBOLU has contributed to areas such as pharmaceutical formulation, drug delivery systems, and therapeutic studies. Her work supports advancements in healthcare applications and contributes to ongoing research efforts in pharmaceutical sciences [2].

Publications

Her publication record includes articles in peer-reviewed journals indexed in international databases. These publications contribute to the dissemination of pharmaceutical research findings and support academic collaboration and citation growth [2].

Research Impact

The citation count and h-index reflect the measurable influence of her work. These indicators suggest engagement with the research community and the relevance of her studies within the pharmaceutical domain [1].

Award Suitability

Based on her academic output, citation metrics, and subject specialization, KRISHNAVENI MANUBOLU demonstrates eligibility for research excellence recognition. Her contributions align with evaluation criteria commonly applied in academic award assessments.

Conclusion

KRISHNAVENI MANUBOLU’s academic profile reflects consistent research engagement and contribution to pharmaceutical sciences. Her publication record and citation metrics support her recognition within the academic community and justify consideration for research excellence awards.

References

  1. Elsevier. (n.d.). Scopus author details: KRISHNAVENI MANUBOLU, Author ID 57222627724. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57222627724

  2. Metal Oxide Nanocatalysts: Eco-friendly Solutions for Catalysis in Green Chemistry.
    https://onlinelibrary.wiley.com/doi/abs/10.1002/9783527853892.ch17

  3. A Short Guide to Clinical Pharmacokinetics.
    https://link.springer.com/book/10.1007/978-981-97-4283-7

  4. Best Paper Awards. (n.d.). Research excellence evaluation criteria.
    https://bestpaperawards.com/

Dr. Kakali Purkayastha | Pharmacology | Research Excellence Award

Published on by Best Paper Awards

Dr. Kakali Purkayastha | Pharmacology | Research Excellence Award

Consultant | ICMR HeadQuarters | India

Dr. Kakali Purkayastha is a researcher known for contributions to interdisciplinary scientific studies, with a professional record spanning academic and applied research environments. Her professional experience includes collaborative projects, publications, and mentoring roles that reflect scholarly engagement. Her research interests focus on scientific domains, emphasizing innovation and practical impact. She possesses research skills in data analysis, experimental design, and scientific communication. Her awards and honors recognize excellence and dedication to research advancement. Overall, her work demonstrates commitment to knowledge development and impactful scholarship. She has achieved 98 Citations, 4 Documents, 4 h-index.

Citation Metrics (Scopus)

100
50
0

98
Citations

4
Documents

4
h-index

Citations

Documents

h-index

View Scopus Profile

Featured Publications

Paula Abola | Pharmacology | Editorial Board Member

Published on by Best Paper Awards

Mrs. Paula Abola | Pharmacology | Editorial Board Member

PhD Student and Professor | University of Jamestown | Germany

Paula Abola is an emerging clinical research scholar whose academic and scientific contributions reflect a strong interdisciplinary foundation in medicinal chemistry, drug development, and neurodegenerative disease research, particularly Parkinson’s disease. She is currently pursuing a PhD in Clinical Research at the University of Jamestown, building on her Master of Science in Clinical Drug Development from Queen Mary University of London and her Bachelor of Science in Medicinal Chemistry and Chemical Biology from Jacobs University Bremen. Her research portfolio demonstrates a growing specialization in movement disorders, with multiple peer-reviewed publications addressing both pharmacological and non-pharmacological management of Parkinson’s disease. Her work includes systematic reviews and meta-analyses evaluating key therapeutic agents such as liquid subcutaneous levodopa-carbidopa (ND0612), rasagiline, and safinamide, focusing on their effects on motor and non-motor symptoms as well as adverse event profiles. Additionally, she has explored innovative technological methodologies for detecting, quantifying, and reducing Parkinsonian tremor, highlighting her interest in rehabilitative and assistive approaches. Abola has also investigated sociodemographic influences on patient and clinician understanding of treatment pathways, contributing meaningful insights into healthcare accessibility, knowledge disparities, and patient-centered care. Her publication on intra-individual variations in voice parameters among individuals with and without Parkinson’s disease further expands her scope into speech-related biomarkers, emphasizing her multidimensional approach to disease assessment. Across her eight documented works, she collaborates frequently with researchers such as Kristin Lefebvre, Mitchell Wolden, and Benjamin Wolden, demonstrating strong engagement in team-based research environments. Overall, Paula Abola’s academic trajectory and scholarly output position her as a dedicated early-career researcher committed to advancing therapeutic strategies, improving diagnostic tools, and deepening understanding of patient experiences within the field of Parkinson’s disease clinical research.

Profile: ORCID

Featured Publications

  1. Abola, P., Lefebvre, K., & Wolden, M. (2025). Influence of sociodemographic variables on patient and practitioner knowledge of pharmacological management options for Parkinson’s disease. American Journal of Medical and Clinical Research & Reviews, 2025.

  2. Abola, P., Lefebvre, K. (2025). Technological advancements in the detection and quantification of Parkinsonian tremor. Topics in Geriatric Rehabilitation, July 2025.

  3. Abola, P., Wolden, M. (2025). Intra-individual variations in voice variables among individuals with and without Parkinson’s disease. Cureus, March 29, 2025.

  4. Abola, P., Wolden, M., & Lefebvre, K. (2024). Liquid subcutaneous levodopa-carbidopa ND0612 effects on motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.

  5. Abola, P., Wolden, M. (2024). Monoamine oxidase-B inhibitor rasagiline effects on motor and non-motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.

Paula Abola’s research advances the understanding and treatment of Parkinson’s disease by integrating clinical evidence, therapeutic evaluation, and emerging diagnostic technologies. Her work contributes to more precise, accessible, and patient-centered care, strengthening global efforts to improve quality of life for individuals with neurodegenerative disorders. She envisions a future where innovative clinical tools and evidence-based interventions enable earlier detection, optimized treatment, and equitable management of neurological conditions worldwide.

Mukesh Ratnaparkhi | Pharmacology | Best Researcher Award

Published on by Best Paper Awards

Dr. Mukesh Ratnaparkhi | Pharmacology | Best Researcher Award 

Professor | Marathwada Mitramandals College of Pharmacy | India

Dr. Mukesh P. Ratnaparkhi, a distinguished pharmaceutical scientist with over 19 years of academic and research experience, demonstrates strong suitability for a Best Researcher Award through his extensive contributions to pharmaceutics, drug delivery systems, and formulation science. Currently serving as a Professor in Pharmaceutics at Marathwada Mitra Mandal’s College of Pharmacy, Pune, he has progressed through roles of increasing responsibility and is an approved Associate Professor, postgraduate teacher, and Ph.D. research guide under Savitribai Phule Pune University. His academic foundation includes a Ph.D. in Pharmaceutical Sciences and a Master’s degree in Pharmaceutics, complementing his long-standing commitment to research. Dr. Ratnaparkhi has an impressive research portfolio with 74 publications in reputed Scopus, Web of Science, UGC Care, and international indexed journals, addressing critical pharmaceutical challenges such as solubility enhancement, nanoformulations, targeted pulmonary delivery, nasal drug delivery, and advanced drug dispersion techniques. His work spans nanosponge systems, nanoemulgels, cubosomes, solid dispersions, and dry powder inhalation formulations, signifying his expertise in innovative and translational drug delivery approaches. He holds four patents (three granted and one filed), demonstrating originality and innovation, and has guided or collaborated on numerous research projects. Complementing his publication record, he has delivered 31 scientific presentations at national and international conferences, showcasing the continued relevance and impact of his research. His professional strengths include excellent communication, leadership, team management, and a strong research orientation, supported by early industrial training that broadened his practical understanding of pharmaceutical processes. With nearly two decades of academic service, consistent research productivity, significant innovation, mentorship roles, and contributions that influence modern drug delivery systems, Dr. Ratnaparkhi exemplifies the qualities of a high-impact researcher and stands as a strong candidate for the Best Researcher Award.

Profiles: Google Scholar | ORCID | Scopus | ResearchGate | LinkedIn

Featured Publications

  1. Ratnaparkhi, M. P., & Suryawanshi, A. N. (2025). Development and characterization of novel cilnidipine-loaded nanosponge formulations. International Journal of Drug Delivery Technology, 15(3), 1198–1204.

  2. Kshirsagar, S. D., & Ratnaparkhi, M. (2025). Formulation and evaluation of propolis loaded nanosponges based topical anti-inflammatory gel. Indian Journal of Pharmaceutical Education and Research, 59(4), 1–11.

  3. Tekade, A., Ratnaparkhi, M., Shewale, A., Shinde, R., Kulkarni, G., & Pawar, P. (2025). Design and assessment of in situ nasal gel incorporated with nanostructured cubosomes for the targeted therapy of schizophrenia. Journal of Research in Pharmacy, 29(3), 947–958.

  4. Ratnaparkhi, M., Binawade, B., Salvankar, S., Aswar, M., Jadhav, P., Parhad, P., Bhangare, S., & Dalvi, S. (2025). Intravaginal administration of metformin HCl loaded nanoemulgel for treatment of PCOS: In-vitro and in-vivo study. Brazilian Journal of Pharmaceutical Sciences.

  5. Ratnaparkhi, M. P., Tekade, A. R., Salvankar, S. S., Dalvi, S. D., Kulkarni, G. M., & Markand, M. G. (2025). RP-HPLC method development and validation for the quantification of remdesivir IV formulation. Indian Drug, 62(6), 45–49.

Dr. Ratnaparkhi’s research advances innovative drug-delivery systems that enhance therapeutic efficiency and patient outcomes. His work contributes to modern pharmaceutical science by translating nanotechnology-based formulations into practical healthcare solutions with global impact.

Pharmacology

Published on by Best Paper Awards

Introduction of Pharmacology:

Pharmacology research is at the heart of understanding how drugs and substances interact with the human body.

Drug Discovery and Development:

Investigating the identification, design, and development of new drugs and therapies to treat a wide range of medical conditions.

Pharmacokinetics and Pharmacodynamics:

Studying how drugs are absorbed, distributed, metabolized, and eliminated in the body and how they exert their effects.

Toxicology:

Analyzing the adverse effects of drugs and chemical on living organisms, including risk assessment and safety evaluation.

Pharmacogenomics:

Exploring the genetic factors influencing drug responses and tailoring treatments to individual genetic profiles for personalized medicine.

Neuropharmacology:

Investigating the effects of drugs on the nervous system, including the development of medications for neurological and psychiatric disorders.